These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
486 related articles for article (PubMed ID: 33391531)
1. Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of Han YJ; Lee KH; Yoon S; Nam SW; Ryu S; Seong D; Kim JS; Lee JY; Yang JW; Lee J; Koyanagi A; Hong SH; Dragioti E; Radua J; Smith L; Oh H; Ghayda RA; Kronbichler A; Effenberger M; Kresse D; Denicolò S; Kang W; Jacob L; Shin H; Shin JI Theranostics; 2021; 11(3):1207-1231. PubMed ID: 33391531 [No Abstract] [Full Text] [Related]
2. Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials. Lai CC; Chao CM; Hsueh PR J Microbiol Immunol Infect; 2021 Oct; 54(5):767-775. PubMed ID: 34253490 [TBL] [Abstract][Full Text] [Related]
3. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks. Wooding DJ; Bach H Clin Microbiol Infect; 2020 Oct; 26(10):1436-1446. PubMed ID: 32791241 [TBL] [Abstract][Full Text] [Related]
4. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus. Martinez MA Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082 [TBL] [Abstract][Full Text] [Related]
5. Current views on the potentials of convalescent plasma therapy (CPT) as Coronavirus disease 2019 (COVID-19) treatment: A systematic review and meta-analysis based on recent studies and previous respiratory pandemics. Aviani JK; Halim D; Soeroto AY; Achmad TH; Djuwantono T Rev Med Virol; 2021 Nov; 31(6):e2225. PubMed ID: 33621405 [TBL] [Abstract][Full Text] [Related]
6. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Chai KL; Valk SJ; Piechotta V; Kimber C; Monsef I; Doree C; Wood EM; Lamikanra AA; Roberts DJ; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N Cochrane Database Syst Rev; 2020 Oct; 10():CD013600. PubMed ID: 33044747 [TBL] [Abstract][Full Text] [Related]
7. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927 [TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis. Kim MS; An MH; Kim WJ; Hwang TH PLoS Med; 2020 Dec; 17(12):e1003501. PubMed ID: 33378357 [TBL] [Abstract][Full Text] [Related]
10. Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis. Simmons B; Wentzel H; Mobarak S; Eslami G; Sadeghi A; Ali Asgari A; Abbaspour Kasgari H; Tirgar Fakheri H; Merat S; Hill A J Antimicrob Chemother; 2021 Jan; 76(2):286-291. PubMed ID: 33063117 [TBL] [Abstract][Full Text] [Related]
12. Severe Acute Respiratory Distress Syndrome Secondary to Coronavirus 2 (SARS-CoV-2). Maveddat A; Mallah H; Rao S; Ali K; Sherali S; Nugent K Int J Occup Environ Med; 2020 Oct; 11(4):157-178. PubMed ID: 33098401 [TBL] [Abstract][Full Text] [Related]
13. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research. Bimonte S; Crispo A; Amore A; Celentano E; Cuomo A; Cascella M In Vivo; 2020 Jun; 34(3 Suppl):1597-1602. PubMed ID: 32503817 [TBL] [Abstract][Full Text] [Related]
14. An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics. Wang D; Li Z; Liu Y J Infect Public Health; 2020 Oct; 13(10):1405-1414. PubMed ID: 32684351 [TBL] [Abstract][Full Text] [Related]
15. [The praise of uncertainty: a systematic living review to evaluate the efficacy and safety of drug treatments for patients with covid-19.]. Cruciani F; Amato L; De Crescenzo F; Mitrova Z; Saulle R; Vecchi S; Davoli M Recenti Prog Med; 2021 Mar; 112(3):195-206. PubMed ID: 33687358 [TBL] [Abstract][Full Text] [Related]
16. Rapid review for the anti-coronavirus effect of remdesivir. Li Z; Wang X; Cao D; Sun R; Li C; Li G Drug Discov Ther; 2020; 14(2):73-76. PubMed ID: 32378648 [TBL] [Abstract][Full Text] [Related]
17. Convalescent Plasma Therapy for COVID-19: Lessons from SARS-CoV, MERS-CoV, and H1N1 Infection. Hosseini P; Rahimi H; Najafabadi MM; Ghorbani A; Najafabadi SK; Faridzadeh A; Arabpour J; Khormali E; Deravi N Acta Med Indones; 2021 Jan; 53(1):86-95. PubMed ID: 33818411 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of sofosbuvir plus daclatasvir or ravidasvir in patients with COVID-19: A randomized controlled trial. Abbass S; Kamal E; Salama M; Salman T; Sabry A; Abdel-Razek W; Helmy S; Abdelgwad A; Sakr N; Elgazzar M; Einar M; Farouk M; Saif M; Shehab I; El-Hosieny E; Mansour M; Mahdi D; Tharwa ES; Salah M; Elrouby O; Waked I J Med Virol; 2021 Dec; 93(12):6750-6759. PubMed ID: 34379337 [TBL] [Abstract][Full Text] [Related]
19. Clinical Trials of Repurposed Antivirals for SARS-CoV-2. Martinez MA Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826 [TBL] [Abstract][Full Text] [Related]
20. Studies on viral pneumonia related to novel coronavirus SARS-CoV-2, SARS-CoV, and MERS-CoV: a literature review. Liya G; Yuguang W; Jian L; Huaiping Y; Xue H; Jianwei H; Jiaju M; Youran L; Chen M; Yiqing J APMIS; 2020 Jun; 128(6):423-432. PubMed ID: 32363707 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]